Stockscreener 앱 받기
3.15
1.61%
0.05
전일 마감가:
$3.10
열려 있는:
$3.03
하루 거래량:
5.55M
Relative Volume:
1.76
시가총액:
$242.82M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-0.9968
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-73.95%
1개월 성능:
-66.67%
6개월 성능:
-76.82%
1년 성능:
-69.94%
1일 변동 폭
$3.02
$3.245
1주일 범위
$2.68
$13.24
52주 변동 폭
$2.68
$17.00
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
3.15 | 238.97M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire
Replimune Group (NASDAQ:REPL) Cut to “Underperform” at BMO Capital Markets - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Equal Weight” at Barclays - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Neutral” at HC Wainwright - Defense World
[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors - TradingView
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Is Replimune Group Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Ongoing Replimune Group, Inc. (REPL) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline - FinancialContent
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Replimune Group (NASDAQ:REPL) Cut to “Hold” at Leerink Partnrs - Defense World
Replimune Group (NASDAQ:REPL) Cut to Hold at Cantor Fitzgerald - Defense World
Shareholder Alert: Robbins LLP Informs Investors of The Replimune Group, Inc. Class Action - ACCESS Newswire
REPL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Replimune Group and the Biotech Litigation Time Bomb: Evaluating Risks in a High-Stakes Sector - AInvest
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL - Business Wire
Shareholders Alert: Investigation Into Replimune Group, Inc. (REPL)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire
REPL ACTIVE INVESTIGATION: Lost Money on Replimune Group, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors - GlobeNewswire
What analysts say about Replimune Group Inc. stockExceptional trading results - Autocar Professional
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action InvestigationREPL - Morningstar
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on ... - Bluefield Daily Telegraph
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor ConcernsHagens Berman - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Replimune Group (REPL.O) Surges 34%—What’s Behind the Sharp Intraday Move? - AInvest
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
Replimune Viral-Based Therapy for Melanoma Rejected By FDA - Inside Precision Medicine
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities - GlobeNewswire
Replimune Group (NASDAQ:REPL) Hits New 12-Month Low Following Analyst Downgrade - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $21.00 Consensus Target Price from Analysts - Defense World
BMO Capital downgrades Replimune stock to Underperform after CRL - Investing.com Australia
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
Barclays downgrades Replimune Group stock rating to Equalweight on FDA rejection - Investing.com Nigeria
Did You Suffer Losses in Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Replimune Group Surges to 445th in Trading Volume with $255 Million Day Despite 77 Percent Stock Drop - AInvest
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
0.97%
0.22%
자본화:
|
볼륨(24시간):